FBRX - CIK 0001419041
The table below shows Forte Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.81M | -$10.36M | -$6.67M | -$5.20M | -$1.98M | -$4.03M |
| Capital expenditure | $0.00 | $61.00K | $6.00K | - | - | - |
| Investing cash flow | $0.00 | $36.29M | -$6.00K | - | - | - |
| Dividends paid | - | - | - | - | - |
Forte Biosciences, Inc. reported operating cash flow of -$50.88M for fiscal year 2025. That is down 65.5% from -$30.75M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$29.54M (FY 2016) to -$50.88M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $74.00K | -$2.32M | -$8.00K | $6.00K | -$34.00K | $27.00K |